Latest Headlines

  1. AcornMed Selects Twist Bioscience Technology To Power Next Generation Precision Medicine Tests 4/8/2021

    AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed’s portfolio of tests designed to provide insight into the genetic predisposition and treatment regimens for patients, providing a more targeted therapeutic approach.

  2. 2D Code Reader With Unique Active Anti-Frost System 4/7/2021

    Micronic is pleased to announce the release of the new Rack Reader DR710, complete with the intuitive Micronic Code Reader Software. The DR710 is equipped with a deep focus image sensor ensuring the highest accuracy 2D code reading even if the tubes aren't flush with the scanner plate or codes are partially compromised.

  3. Tesis Labs Launching New Arizona Genetic Testing Facility 4/7/2021

    Tesis Labs, the leader in targeted genetic sequencing, announced its plans to expand to the Phoenix/Scottsdale area, offering targeted genetic sequencing services to healthcare providers in the western U.S. The new lab will be located in Scottsdale.

  4. Roche Launches Elecsys Anti-p53 Immunoassay To Aid Diagnosis Of Various Cancer Types 4/7/2021

    Roche today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This test is used to aid physicians to diagnose oesophageal cancer, bowel cancer and breast cancer in patients, in conjunction with other diagnostic tests. The assay is now available for all markets accepting the CE Mark.

  5. ARCEDI Biotech Announces Availability Of EVITA TEST COMPLETE™ First Prenatal Genetic Blood Test To Identify And Isolate Fetal Cells In Maternal Blood 4/6/2021

    ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced the launch of EVITA TEST COMPLETE™ (EVITA), the first prenatal genetic blood test to identify and isolate fetal cells in maternal blood.

  6. NorthShore University HealthSystem And GoPath Laboratories Partner To Offer The Most Comprehensive Inherited Risk Assessment For Prostate Cancer With PROSTATENOW™ 4/6/2021

    NorthShore University HealthSystem (NorthShore) and GoPath Laboratories have announced a novel partnership to launch a new genetics test that assesses the inherited risk for prostate cancer using three methods: family history, rare pathogenic mutations and genetic risk score.

  7. Invitae To Acquire Genosity To Accelerate Access To Personalized Oncology Testing Worldwide 4/5/2021

    Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests.

  8. Ethos Laboratories Launches High-Throughput SARS-CoV-2 Variant Assay To Monitor Emerging Coronavirus Mutations 4/5/2021

    Ethos Laboratories®, a national leader in laboratory testing, has announced the validation of a high-throughput molecular test for the detection of key SARS-CoV-2 virus strains, including the UK (B.1.1.7), South Africa (B.1.351), Brazil (P.1) variants.

  9. StageZero Life Sciences Introduces Aristotle, The First Multi-Cancer Test From A Single Sample Of Blood 4/5/2021

    StageZero Life Sciences, Ltd ("StageZero" or the "Company") on Thursday April 1st, announced it was partnering with Health Clinics and Care Oncology to launch the early cancer diagnostic program AVRT centered around Aristotle, StageZero's multi-cancer test.

  10. Quidel’s Sofia SARS Antigen Test Receives Emergency Use Authorization For Screening Use With Serial Testing 4/2/2021

    Quidel Corporation (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing the company to market its Sofia SARS Antigen FIA for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from anterior nares swab specimens directly from individuals who are either suspected of COVID-19.